Impact of treatment-induced neutropenia and thrombocytopenia on survival in patients with advanced ovarian cancer treated with chemotherapy plus bevacizumab: an NRG Oncology/Gynecologic Oncology Group ancillary data study

Tewari, Krishnansu

57
Impact of treatment-induced neutropenia and thrombocytopenia on survival in patients with advanced ovarian cancer treated with chemotherapy plus bevacizumab: an NRG Oncology/Gynecologic Oncology Group ancillary data study

Tuesday, March 31, 2015: 10:02 AM

International Ballroom (Hilton Chicago)

K. S. Tewari¹, J. Java², R. N. Eskander³, B. J. Monk⁴ and R. A. Burger⁵
¹UC Irvine Medical Center, Orange, CA, ²Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, ³University of California at Irvine Medical Center, Orange, CA, ⁴University of Arizona Cancer Center, Phoenix, AZ, ⁵University of Pennsylvania, Philadelphia, PA

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

57
Impact of treatment-induced neutropenia and thrombocytopenia on survival in patients with advanced ovarian cancer treated with chemotherapy plus bevacizumab: an NRG Oncology/Gynecologic Oncology Group ancillary data study

57 Impact of treatment-induced neutropenia and thrombocytopenia on survival in patients with advanced ovarian cancer treated with chemotherapy plus bevacizumab: an NRG Oncology/Gynecologic Oncology Group ancillary data study

57
Impact of treatment-induced neutropenia and thrombocytopenia on survival in patients with advanced ovarian cancer treated with chemotherapy plus bevacizumab: an NRG Oncology/Gynecologic Oncology Group ancillary data study